ASP Isotopes Inc.ASPI

ASP Isotopes Inc. has set a bold public target: EBITDA greater than $300 million by 2031, a figure that sounds heroic until you open the company’s latest 10-Q for the quarter ended March 31, 2026, and find a net loss attributable to shareholders of $7.1 million, an operating loss of $24.9 million, and cash used in operations of $17.8 million. The slide deck’s future tense sits uneasily alongside the balance sheet’s present-tense red ink.

ASP Isotopes describes itself as an advanced materials company developing proprietary enrichment technologies-the Aerodynamic Separation Process and QE technology-intended to supply isotopes for nuclear medicine, next-generation semiconductors, and nuclear energy. The filing proudly notes that commercial production at ASP’s enrichment facilities in Pretoria started in the first half of 2025, yet the same document states that as of March 31, 2026, the company has not generated any revenue from the sale of enriched isotopes. In other words, the factory is running, but the customers are not.

The balance sheet offers some comfort: total assets of $587.7 million, including $207.3 million in cash and cash equivalents and $83.2 million in short-term investments. Stockholders’ equity stands at $289.0 million, and the company has used $6.1 million on property, plant, and equipment in the quarter, with a further $5.3 million spent on research and development. Inventory has crept up by $208,000 to $1.4 million, though it is unclear whether this reflects work in progress, finished goods, or just a very patient warehouse. Earnings per share came in at a diluted loss of $0.06 on 121.0 million shares outstanding. The cash burn continues, the revenue dial is still on zero, and the 2031 EBITDA promise remains a promise.

On July 17, 2026, ASP Isotopes and ENDRA Life Sciences issued a joint press release announcing the issuance of the Form S-4, proxy statement, and other documents related to their proposed business combination, all of which will be available via the SEC’s website. The filing parade suggests momentum toward a transaction, but the core business’s operating metrics remain unproven. The company’s technology pages highlight two enrichment facilities: a dedicated C-14 plant in South Africa and an Icelandic cluster planned for 2025-2028, yet neither has translated into shipped revenue in the latest quarter. The disconnect between the technology narrative and the financial reality is the file’s central tension.

For investors accustomed to a more conventional path-build the plant, sell the product, collect the cash-ASP Isotopes offers something more speculative: a long-dated bet on isotope supply chains, a board-mandated EBITDA goal for 2031, and a balance sheet that is solvent but not yet sales-positive. The open question is whether the next 12 months bring first revenues, a deeper cash burn, or another filing update. Until then, the company’s story remains a work in progress, its technology deck polished and its income statement still in draft form.